Eli Lilly and Company $LLY Shares Sold by Prime Capital Investment Advisors LLC

Prime Capital Investment Advisors LLC lessened its stake in shares of Eli Lilly and Company (NYSE:LLY) by 2.2% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 61,753 shares of the company’s stock after selling 1,399 shares during the quarter. Prime Capital Investment Advisors LLC’s holdings in Eli Lilly and Company were worth $71,454,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Maseco LLP raised its holdings in Eli Lilly and Company by 466.7% in the 1st quarter. Maseco LLP now owns 34 shares of the company’s stock valued at $31,000 after acquiring an additional 28 shares during the period. Marshall & Sterling Wealth Advisors Inc. lifted its position in Eli Lilly and Company by 60.0% during the first quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company’s stock worth $37,000 after acquiring an additional 15 shares during the last quarter. AlphaCentric Advisors LLC acquired a new stake in Eli Lilly and Company during the first quarter worth approximately $42,000. Caitlin John LLC acquired a new stake in Eli Lilly and Company during the second quarter worth approximately $64,000. Finally, IMG Wealth Management Inc. boosted its holdings in shares of Eli Lilly and Company by 500.0% during the second quarter. IMG Wealth Management Inc. now owns 60 shares of the company’s stock worth $72,000 after acquiring an additional 50 shares during the period. Institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

LLY has been the topic of several research reports. Wells Fargo & Company upped their target price on Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. TD Cowen reissued a “buy” rating and set a $1,250.00 price target on shares of Eli Lilly and Company in a report on Tuesday, September 22nd. Berenberg Bank set a $1,400.00 price target on Eli Lilly and Company and gave the company a “buy” rating in a research note on Tuesday, September 15th. JPMorgan Chase & Co. boosted their price target on Eli Lilly and Company from $1,400.00 to $1,500.00 and gave the company an “overweight” rating in a research note on Monday, September 28th. Finally, Weiss Ratings raised Eli Lilly and Company from a “buy (b)” rating to a “buy (b+)” rating in a report on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $1,317.93.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $1,271.89 on Thursday. Eli Lilly and Company has a twelve month low of $793.82 and a twelve month high of $1,311.75. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The company has a 50-day simple moving average of $1,182.84 and a two-hundred day simple moving average of $1,116.53. The stock has a market capitalization of $1.20 trillion, a price-to-earnings ratio of 42.68, a price-to-earnings-growth ratio of 1.71 and a beta of 0.46.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The firm had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. During the same quarter in the previous year, the firm posted $6.31 EPS. The business’s revenue for the quarter was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Analysts forecast that Eli Lilly and Company will post 33.56 EPS for the current year.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Higher analyst target and expected earnings strength: Goldman Sachs raised its price target to $1,413 from $1,371 while maintaining a Buy rating. The firm reportedly expects Eli Lilly to beat third-quarter estimates and raise its outlook, supported by international Mounjaro growth and Zepbound volume gains. Goldman Sachs raises Eli Lilly price target
• Positive Sentiment: International manufacturing expansion: Eli Lilly signed Abu Dhabi agreements involving local packaging and advanced pharmaceutical contract manufacturing for weight-loss medicines. The company also entered a drug-delivery partnership with China’s Metis TechBio valued at up to $1.1 billion, potentially strengthening supply capacity and product-delivery capabilities. Eli Lilly Abu Dhabi packaging deal
• Positive Sentiment: Pipeline expansion: One-year Phase 3 SHINE-2 data showed Omvoh sustained clinical-remission benefits in children with ulcerative colitis, including patients who had previously failed biologic treatments. Regulatory approval could expand Lilly’s inflammatory bowel disease franchise. Pediatric ulcerative colitis data
• Neutral Sentiment: Strong growth, but pricing is a key upcoming issue: Second-quarter revenue increased 48% to approximately $23 billion as medicine volume rose 60%, while realized price per unit declined 13%. Investors will focus on whether continued demand and volume growth can offset pricing pressure when third-quarter results are released on October 29. Eli Lilly volume and pricing analysis
• Negative Sentiment: Competition and valuation risks: Novo Nordisk’s CagriSema produced 25% weight loss in women, reinforcing competitive pressure in the obesity-treatment market. After a substantial rally and record valuation, investors may also be taking profits or demanding stronger evidence that Lilly’s growth can justify its premium multiple. Novo Nordisk CagriSema results

Insider Transactions at Eli Lilly and Company

In other news, EVP Patrik Jonsson sold 6,500 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the sale, the executive vice president directly owned 54,147 shares in the company, valued at approximately $63,628,139.70. The trade was a 10.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald Zakrowski sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the sale, the chief accounting officer owned 1,526 shares of the company’s stock, valued at approximately $1,808,325.26. This trade represents a 56.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 13,500 shares of company stock valued at $15,958,170. 0.14% of the stock is currently owned by company insiders.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.